Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EAGLE PHARMACEUTICALS, INC.
Report date May 15, 2017 · Filed May 15, 2017
Jointly reported with ProQuest Investments IV, L.P., ProQuest Financial LLC, ProQuest Associates IV LLC, Moorin Jay
Section 16 reporting ended · disclosed 2017-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy ProQuest Investments IV, L.P. | 0 |
Reported balance
After 2017-05-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-05-15 · Other · Disposed 3,584,087 · Balance 0 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. F1: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy Jay Moorin directly and through IRA | 172,381 |
Reported balance
After 2017-05-15 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2017-05-15 · Other · Acquired 149,107 · Balance 172,381 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy Alain Schreiber | 149,107 |
Reported balance
After 2017-05-15 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2017-05-15 · Other · Acquired 149,107 · Balance 149,107 F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration. |
| Common Stock $0.001 par valueSEC Table I · non-derivative | IndirectBy ProQuest Financial LLC | 6,777 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,777 F2: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
F2: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities.
F3: Effective as of May 15, 2017, Investments IV distributed the shares to its partners for no additional consideration.
UroGen Pharma Ltd.
Report date November 27, 2017 · Filed November 29, 2017
Jointly reported with ProQuest Investments IV, L.P., ProQuest Associates IV LLC, Moorin Jay
Section 16 reporting ended · disclosed 2017-11-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per shareSEC Table I · non-derivative | Direct | 1,242,031 |
Last balance in matching sequence
After 2017-11-28 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-11-27 · Sale · Disposed 31,491 · Balance 1,419,838 F2: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. Row 2 · 2017-11-28 · Sale · Disposed 177,807 · Balance 1,242,031 F3: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by ProQuest Investments IV, L.P. and indirectly held by ProQuest Associates IV, LLC, the General Partner of ProQuest Investments IV, L.P. The individual managing members of ProQuest Associates IV, LLC are Jay Moorin and Alain Schreiber, M.D., who may be deemed to have shared voting and investment and dispositive power with respect to these shares. Each individual managing member disclaims beneficial ownership of these shares, except to the extent of their pecuniary interest in such shares.
F2: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $41.00 to $41.68. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
F3: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $40.50 to $41.01. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 4,200 | $78.23 | $328,566.00 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,099,787 F8 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $78.00 to $78.62. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 9,030 | $77.13 | $696,483.90 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,103,987 F7 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $77.00 to $77.92. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 11,690 | $76.49 | $894,168.10 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,113,017 F6 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $76.00 to $76.99. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 09, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,380 | $75.70 | $104,466.00 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,124,707 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $75.27 to $75.95. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 17:52 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 5,030 | $75.39 | $379,211.70 |
DisclosureSEC source: 0000932440-16-000521 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,126,087 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $75.00 to $76.00. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F4 · balance_after: This number shows a corrected balance reflecting a decrease of 50,329 shares, due to adminstrative error. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 04, 2016 Filed Nov 4, 2016 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 46,170 | $75.00 | $3,462,750.00 |
DisclosureSEC source: 0000932440-16-000508 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,181,446 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $75.00 to $75.11 The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 2,100 | $70.00 | $147,000.00 |
DisclosureSEC source: 0000932440-16-000508 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 27,474 Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 800 | $70.00 | $56,000.00 |
DisclosureSEC source: 0000932440-16-000508 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 7,977 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 50,329 | $70.41 | $3,543,664.89 |
DisclosureSEC source: 0000932440-16-000508 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,177,287 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $70.11 to $71.08. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 17:07 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 146,371 | $70.00 | $10,245,970.00 |
DisclosureSEC source: 0000932440-16-000508 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,227,616 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $70.00 to $70.10. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:20 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 22,100 | $70.06 | $1,548,326.00 |
DisclosureSEC source: 0000932440-16-000495 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,373,987 F2 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $70.00 to $70.38. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 29, 2016 Filed Sep 30, 2016 16:15 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 77,900 | $70.04 | $5,456,116.00 |
DisclosureSEC source: 0000932440-16-000493 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,396,087 F2 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $70.00 to $70.23. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:15 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 654 | $66.17 | $43,275.18 |
DisclosureSEC source: 0000932440-16-000485 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 29,574 Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:15 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 194 | $66.17 | $12,836.98 |
DisclosureSEC source: 0000932440-16-000485 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 8,777 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:15 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 1,798 | $67.24 | $120,897.52 |
DisclosureSEC source: 0000932440-16-000485 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,473,987 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $67.03 to $67.47. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 17:15 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 97,149 | $66.15 | $6,426,406.35 |
DisclosureSEC source: 0000932440-16-000485 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,475,785 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $66.00 to $66.99. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 08, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 224 | $62.33 | $13,961.92 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 10 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 30,228 Read SEC document |
| September 08, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 66 | $62.33 | $4,113.78 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 9 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 8,971 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 08, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 33,796 | $62.33 | $2,106,504.68 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 8 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, LP Disclosed balance after: 4,572,934 F6 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $62.25 to $62.59. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 07, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 75 | $62.26 | $4,669.50 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 7 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 30,452 Read SEC document |
| September 07, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 22 | $62.26 | $1,369.72 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 6 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 9,037 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 07, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 11,345 | $62.26 | $706,339.70 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 5 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,606,730 F5 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $62.25 to $62.40. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 166 | $62.83 | $10,429.78 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 4 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Jay Moorin through IRA Disclosed balance after: 30,527 Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 49 | $62.83 | $3,078.67 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 3 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Financial LLC Disclosed balance after: 9,059 F2 · ownership.nature: Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 12,224 | $63.25 | $773,168.00 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 2 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, LP Disclosed balance after: 4,618,075 F4 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $63.03 to $63.42. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:01 UTC | EAGLE PHARMACEUTICALS, INC. EGRX · Entity 85958 | SaleCommon Stock $0.001 par value | 12,958 | $62.45 | $809,227.10 |
DisclosureSEC source: 0000932440-16-000471 · edgar.xml · nonDerivative · entry 1 ProQuest Investments IV, L.P. · CIK 0001431818 · 10% owner ProQuest Financial LLC · CIK 0001674772 · 10% owner ProQuest Associates IV LLC · CIK 0001431819 · 10% owner Moorin Jay · CIK 0001033508 · 10% owner SCHREIBER ALAIN · CIK 0001225149 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By ProQuest Investments IV, L.P. Disclosed balance after: 4,630,299 F3 · price: Constitutes the weighted average purchase price for multiple transactions reported on this line having prices per share ranging from $62.25 to $62.93. The Reporting Persons will provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding each separate transaction. F1 · ownership.nature: The shares are held by ProQuest Investments IV, L.P. ("Investments IV"), which ProQuest Financial LLC ("ProQuest Financial") manages. Jay Moorin and Alain Schreiber are managing members of ProQuest Financial and each of them disclaims beneficial ownership of such securities except to the extent of his pecuniary interest in such securities. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.